Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

PURPOSE: Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules of etirinotecan pegol in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Vergote, Ignace B., Garcia, Agustin, Micha, John, Pippitt, Charles, Bendell, Johanna, Spitz, Daniel, Reed, Nicholas, Dark, Graham, Fracasso, Paula M., Ibrahim, Emad N., Armenio, Vincent A., Duska, Linda, Poole, Chris, Gennigens, Christine, Dirix, Luc Y., Leung, Abraham C.F., Zhao, Carol, Soufi-Mahjoubi, Raoudha, Rustin, Gordon
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2013
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878105/
https://ncbi.nlm.nih.gov/pubmed/24081946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.1278
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky